Elevance: making the US healthcare insurance system’s maze manageable

Please remember that the value of an investment can fall and you may not get back the amount invested.

Thinking about the US healthcare system brings Global Alpha's Malcolm MacColl out in a cold sweat. The care it provides for sick Americans is, he says, notoriously inconsistent, expensive and hard to navigate.

“The United States is an amazing country, but its healthcare provision is dreadfully uncoordinated,” the deputy manager of The Monks Investment Trust says. “The primary care provider and the health insurer are not always joined up terribly well. In aspects such as the management of health records, it’s just appalling.”

As for the cost for the average family, premiums for the commonest kind of private healthcare insurance rose by 47 per cent between 2011 and 2021, more than twice the inflation rate.

So it may come as a surprise that Elevance Health is one of Global Alpha's biggest holdings. The firm declared itself the US’s biggest medical insurer in October 2022 after reporting 5 per cent annual growth in the number of people it covers. It now serves more than 47 million Americans. And to signal its further ambitions, it has rebranded itself, ditching its former name Anthem.

As MacColl explains, Elevance’s scale helps address some of the shortcomings of the US healthcare system in terms of patients finding their way through its maze and reducing operational costs.

“The client wants as broad a coverage network as possible,” he says. “They don’t want to be told: ‘Sorry, you can’t see that clinician.’ So having scale enables Elevance to better look after its customers. And because there’s a huge administrative aspect to the business, the more volume the company can put through its system, the more it can spread its fixed costs.”

Private insurance plans

In a country where about 90 per cent of the population has some form of private health insurance (the UK figure is 13 per cent), the company offers two types of plan:

• Fully insured – Elevance assumes the financial risk of a member’s medical claims.

   

• Administrative services only – Elevance typically provides the same services as above, including claims processing, medical management and other customer services. But it only receives an administrative fee because the member’s employer or other liable party pays for the claims incurred.

MacColl contends that both halves of the business are set to grow under the leadership of its formidable chief executive, Gail Boudreaux (see box, below). And because the wider market is generally sceptical about insurance, other investors underappreciate the opportunity.

“It’s a dream for a growth investor because the market hasn’t yet recognised its true value,” he says.

He says demographics will be the critical driver of the fully insured side of the business. Baby boomers are retiring and taking on responsibility for their own insurance.

Elevance aims to build its market share for this ageing group of citizens to close to 30 per cent, roughly the level it has already achieved in the commercial sector.

One way it plans to do so is by marketing its Medicare Advantage plans to those about to leave work. The government-subsidised scheme covers hospital and doctors’ costs and, in most cases, certain drugs and services, such as dental treatment.

Medicare Advantage tends to cost less than alternative Medicare schemes that don’t involve private companies. But the trade-off is that Advantage scheme members can only use medics and other providers in the firm’s network, except in emergencies.

So Elevance’s size gives it a natural advantage over rivals whose networks of caregivers are smaller. And this is reflected in its high customer satisfaction ratings.

“Some investors are nervous about the underwriting aspect of this,” MacColl adds, referring to the firm’s ability to maintain a healthy margin between what it charges and pays out. “But that’s completely misguided here. Elevance reprices very regularly. So even if it were to make a mistake, it’s very easy to correct. And it’s got a fabulous underwriting record.”

Turning to the administrative services only side of the business, MacColl acknowledges that Elevance has historically made less per member than it might have done. But he expects that to change.

“Elevance has arguably got the strongest management it has ever had. And they are driving efficiencies harder and scaling through cross-selling,” he says.

Cross-selling involves convincing employers to sign up for additional services. These can include dental, vision and mental health care, as well as digital tools to let medics remotely monitor patients’ progress.

Before becoming chief executive, Boudreaux increased revenues at the firm’s biggest rival, UnitedHealthcare, by following a similar strategy. And under her command, Elevance has acquired a series of companies to increase its offerings.

Its expansion has also included the enlargement of its pharmacy benefit management division. It acts as an intermediary, creating lists of which drugs different insurance plans cover and negotiating discounts with pharmaceutical manufacturers that want their medicines included – keeping a cut of the savings for itself.

“The story of the next 15 years will be the further development of Elevance’s services business,” MacColl says. “And the opportunity is vast because the scale of the US health system is gigantic.” That’s not to say there aren’t risks.

“You’ve got the potential for regulatory interference and for caps to be put on profitability,” MacColl acknowledges. “But what I think people get wrong is that it’s nigh on impossible to run the US healthcare system without these types of business. And it would be idiotic for the government to sabotage them.”

Long-term compounding

Healthcare insurance is complex, and its providers will never generate the same excitement or rapid growth that electric vehicle makers and other tech companies might.

But what Elevance offers is the prospect of steady compounding, with profits being reinvested in the business over decades to create outsized growth, making it an ideal pick for investors focused on the long term.

“Compounding is a real asset to the growth investor, but it requires patience to work,” MacColl concludes. “And that’s in drastically short supply in financial markets.”

So yes, the broader US healthcare system may be complex and opaque. But as long as Elevance continues to ease patients’ path through the labyrinth, the prognosis for customers and investors looks positive.

Risk Factors

The views expressed should not be considered as advice or a recommendation to buy, sell or hold a particular investment. They reflect opinion and should not be taken as statements of fact nor should any reliance be placed on them when making investment decisions.

This communication was produced and approved in April 2023 and has not been updated subsequently. It represents views held at the time of writing and may not reflect current thinking.

Potential for Profit and Loss

All investment strategies have the potential for profit and loss, your or your clients’ capital may be at risk. Past performance is not a guide to future returns.

This communication contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research, but is classified as advertising under Art 68 of the Financial Services Act (‘FinSA’) and Baillie Gifford and its staff may have dealt in the investments concerned.

All information is sourced from Baillie Gifford & Co and is current unless otherwise stated.

The images used in this communication are for illustrative purposes only.

Important Information

Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs.

Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK Professional/Institutional clients only. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford & Co and Baillie Gifford Overseas Limited are authorised and regulated by the FCA in the UK.

Persons resident or domiciled outside the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

Financial Intermediaries

This communication is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.

Europe

Baillie Gifford Investment Management (Europe) Limited provides investment management and advisory services to European (excluding UK) clients. It was incorporated in Ireland in May 2018. Baillie Gifford Investment Management (Europe) Limited is authorised by the Central Bank of Ireland as an AIFM under the AIFM Regulations and as a UCITS management company under the UCITS Regulation. Baillie Gifford Investment Management (Europe) Limited is also authorised in accordance with Regulation 7 of the AIFM Regulations, to provide management of portfolios of investments, including Individual Portfolio Management (‘IPM’) and Non-Core Services. Baillie Gifford Investment Management (Europe) Limited has been appointed as UCITS management company to the following UCITS umbrella company; Baillie Gifford Worldwide Funds plc. Through passporting it has established Baillie Gifford Investment Management (Europe) Limited (Frankfurt Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in Germany. Similarly, it has established Baillie Gifford Investment Management (Europe) Limited (Amsterdam Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in The Netherlands. Baillie Gifford Investment Management (Europe) Limited also has a representative office in Zurich, Switzerland pursuant to Art. 58 of the Federal Act on Financial Institutions (“FinIA”). The representative office is authorised by the Swiss Financial Market Supervisory Authority (FINMA). The representative office does not constitute a branch and therefore does not have authority to commit Baillie Gifford Investment Management (Europe) Limited. Baillie Gifford Investment Management (Europe) Limited is a wholly owned subsidiary of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co. Baillie Gifford Overseas Limited and Baillie Gifford & Co are authorised and regulated in the UK by the Financial Conduct Authority.

Hong Kong

Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 and a Type 2 license from the Securities & Futures Commission of Hong Kong to market and distribute Baillie Gifford’s range of collective investment schemes to professional investors in Hong Kong. Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲(香港)有限公司 can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong. Telephone +852 3756 5700.

South Korea

Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-discretionary Investment Adviser.

Japan

Mitsubishi UFJ Baillie Gifford Asset Management Limited (‘MUBGAM’) is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and Baillie Gifford Overseas Limited. MUBGAM is authorised and regulated by the Financial Conduct Authority.

Australia

Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This material is provided to you on the basis that you are a “wholesale client” within the meaning of section 761G of the Corporations Act 2001 (Cth) (“Corporations Act”).  Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client.  In no circumstances may this material be made available to a “retail client” within the meaning of section 761G of the Corporations Act.

This material contains general information only.  It does not take into account any person’s objectives, financial situation or needs.

South Africa

Baillie Gifford Overseas Limited is registered as a Foreign Financial Services Provider with the Financial Sector Conduct Authority in South Africa.

North America

Baillie Gifford International LLC is wholly owned by Baillie Gifford Overseas Limited; it was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which Baillie Gifford Overseas Limited provides client service and marketing functions in North America. Baillie Gifford Overseas Limited is registered with the SEC in the United States of America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission ('OSC'). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. Baillie Gifford International LLC is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. Baillie Gifford Investment Management (Europe) Limited (‘BGE’) relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.
 

Israel

Baillie Gifford Overseas is not licensed under Israel’s Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755-1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This material is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.

407405